This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zogenix And Battelle Expand DosePro Technology Business Agreement

SAN DIEGO and COLUMBUS, Ohio, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle today announced that they have entered into a new long-term collaborative agreement regarding co-marketing of Zogenix's DosePro ® needle-free drug delivery technology, advancing potential out-licensing opportunities for DosePro with biopharmaceutical clients, and expanding the application of the technology to higher-dose biologic therapies.

The new five-year contract also establishes Battelle as the preferred provider of development services for the DosePro technology. Zogenix plans to leverage the substantial technical resources and capabilities of Battelle's drug delivery business for expertise in self-injection system design, human factors and device engineering as the companies further develop DosePro targeting dose volumes in excess of 1mL to accommodate a greater number of biopharmaceutical drug candidates.

The companies began co-marketing and product testing in March 2012, and the agreement builds on the success of the companies' relationship since then. During this period, the companies launched the "Less is More" marketing campaign, completed and presented studies supporting the use of DosePro with biologics, and presented patient research demonstrating preference for needle-free injection technology. The research, which queried 300 rheumatoid arthritis patients, demonstrated a significant 30 percent increase in patient acceptance of self-injected medication when a needle-free option was offered. In addition, the companies completed a study that demonstrated the ability of the DosePro technology to effectively deliver a monoclonal antibody therapeutic, AbbVie Inc.'s Humira ® (adalimumab). The in vitro study showed that DosePro can deliver Humira without incremental risk to protein denaturation and equivalent biological integrity as compared to delivery by pre-filled syringe.

John Turanin, Vice President and General Manager, DosePro Technology, at Zogenix, said, "Through our co-marketing agreement with Battelle, we have expanded awareness of the DosePro needle-free drug delivery system. Battelle has proved to be a strong technical and business development ally and interest in the DosePro technology from biopharmaceutical companies has significantly increased because of Battelle's support. We are pleased with our progress and continue to believe there is significant potential to out-license DosePro for the delivery of biologics. Our new 5-year agreement with Battelle underscores both companies' commitment to achieving this goal, which includes executing on near-term and future opportunities."  

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs